4.2 Review

Current state and limitations of daily oral therapy for treatment

期刊

CURRENT OPINION IN HIV AND AIDS
卷 10, 期 4, 页码 219-225

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0000000000000165

关键词

antiretroviral; HIV; limitations; oral; strengths

资金

  1. BMS
  2. Gilead
  3. GSK/ViiV
  4. Merck

向作者/读者索取更多资源

Purpose of reviewWe aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy.Recent findingsCurrent ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden.SummaryCurrent treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据